A New Tool To Peer Inside The Cell
Engineered fluorescent nanobodies that work inside living cells can label multiple proteins in different colors at once, revealing real-time cellular activity.
- Engineered fluorescent nanobodies are derived from llama antibodies and are only 2–3 nanometers in size, far smaller than traditional antibody tags (150 nm).
- The new nanobodies can label up to four distinct proteins in different fluorescent colors simultaneously inside living cells.
- They are reversible: a light-sensitive switch allows researchers to turn labeling on and off at will, enabling pulse-chase experiments.
- The method has already been used to observe signaling proteins during cell division and to track calcium dynamics in neurons.
- Protocols and DNA sequences are freely available, with a commercial kit expected within two years for broad adoption.
- The nanobodies operate in the reducing environment of the cytoplasm, a feat previously considered impossible for antibody-derived probes.
- Researchers demonstrated the tool in cancer cell lines and primary neurons, showing real-time drug-target engagement.
Frequently Asked Questions
Fluorescent nanobodies are tiny antibody fragments from llamas that are engineered to bind to specific proteins inside living cells and glow in different colors under a microscope.
They are designed with mutations that stabilize the protein structure in the reducing environment of the cytoplasm. Once inside, they bind to target proteins and emit fluorescent light, allowing researchers to track movement and interactions in real time.
They show where proteins go, when they interact, and how they change during processes like cell division, stress, or drug treatment. This provides a dynamic view of molecular activity.
Yes, for live-cell imaging. Traditional antibodies are too large and cannot enter living cells easily. Nanobodies are much smaller and can be engineered to work inside the cytoplasm without breaking down.
Yes. They allow researchers to see exactly when and where a drug binds its target inside a living cell, helping to identify off-target effects and improve drug efficacy.
The protocols and DNA sequences have been published open-source, and a commercial kit is expected within two years, making the technology accessible to most molecular biology labs.
Topics
Original source
www.forbes.com
Discussion
Join the discussion
Sign in to post a comment or reply.
No comments yet. Be the first to share your thoughts!